ZLNA — Zelluna ASA Share News
0.000.00%
Last trade - 00:00- NOK544.15m
- NOK451.38m
Brief: Ultimovacs Q1 Operating Loss At NOK 31.3 Million
Brief: Ultimovacs Updates On Possible Impact Of Covid-19
Brief: Ultimovacs Q4 Operating Loss Widens To NOK 27.8 Million
Brief: Ultimovacs Appoints Carlos De Sousa New CEO
Brief: Ultimovacs: Universal Cancer Vaccine To Be Tested In Phase II Trial
Brief: Ultimovacs Q3 Loss For The Period Widens To NOK 17.2 Million
Brief: Ultimovacs H1 Operating Loss Narrows To NOK 19.1 Million
Brief: Ultimovacs Granted European Patent Approval For UV1